EGFR and non-small cell lung carcinoma: Similarly, the EGFR bypass activation pathway can mediate resistance of ROS1 fusion NSCLC to ROS1 TKIs (95), which can be reversed by co-administration of ROS1 and EGFR inhibitors (96, 97).